FDA clears Macro Biologics’ Amicidin-α gel for Phase 1 trial

Macro Biologics received FDA clearance to begin a Phase 1 study of Amicidin-α Surgical Gel in adult surgical-wound patients. The trial will test safety and tolerability as the company moves its infection-prevention biomaterial into clinical development.

Why it matters: - Surgical-site infections can lead to serious complications, longer recovery and higher costs. - Amicidin-α Surgical Gel is designed to protect vulnerable wound tissue and reduce infection risk when applied directly into surgical wounds. - The FDA green light lets Macro Biologics start human testing of a product meant for use in hospitals, operating rooms, emergency departments and military settings.

What happened: - Macro Biologics received a “Study May Proceed” letter from the U.S. Food and Drug Administration for its Investigational New Drug application for Amicidin-α Surgical Gel. - The accepted IND supports a Phase 1 clinical trial titled, “A Phase 1 Study to Assess Safety and Tolerability of Intrawound Application of Amicidin-α Surgical Gel in Adult Patients.” - The study will evaluate safety and tolerability when the gel is applied directly into surgical wounds. - The announcement was made June 18, 2026.

The details: - Amicidin-α is a synthetic amino acid polymer engineered to protect exposed tissues in surgical and traumatic wounds. - The product uses a dual “block and kill” mode of action. - The technology combines a physical barrier with broad microbicidal activity. - Amicidin-α Surgical Gel is being developed initially for direct application into surgical wounds to help reduce serious post-operative infections. - Curapath supported development and manufacturing of both the Amicidin-α drug substance and the gel drug product. - Curapath’s work covered early process development, GMP manufacturing, IND support and supply of clinical trial material. - Macro Biologics said the Amicidin platform is backed by a strong intellectual property portfolio. - The company designs, patents and produces biomaterials for healthcare, clean water and food, and better packaging. - Curapath is a CDMO focused on polymer- and lipid-based therapeutics, drug delivery systems and nanoparticle technologies. - Amicidin-α Surgical Gel is investigational and has not been approved by the FDA for commercial use.

Between the lines: - The FDA clearance signals a transition from preclinical development to clinical validation, which is the first major hurdle for a wound-protection biomaterial. - Macro Biologics is positioning Amicidin-α as a platform technology for infection prevention, not just a single-use surgical product. - The company’s emphasis on high-risk care settings suggests a target market where infection prevention has outsized clinical value. - Curapath’s role shows the program already has manufacturing infrastructure in place, which can matter as programs move toward larger trials.

What's next: - Macro Biologics will begin the Phase 1 study in adult patients. - The trial will focus on safety and tolerability before any broader efficacy testing. - Further clinical development will depend on the results of this early-stage study.

The bottom line: - FDA clearance gives Macro Biologics a path to test whether Amicidin-α Surgical Gel can safely protect surgical wounds and lower infection risk in people.